Skip to main content

Table 3 Contraindications to carbapenem sparing agents

From: Clinical syndromes and treatment location predict utility of carbapenem sparing therapies in ceftriaxone-non-susceptible Escherichia coli bloodstream infection

Antimicrobial Total Rash Anaphylaxis SCAR Pregnancy Heart failurea Cirrhosis Non-urinary tract source Renal impairmente
Ceftolozane-tazobactam 2 1 1 0
Ceftazidime-avibactam 2 1 1 0 0
Plazomicinb 42 0 0 0 0 26 21
Fosfomycinc 32 0 0 0 4 3 25 1
Cefiderocold 26 1 1 0 0 26
  1. SCAR severe cutaneous adverse reaction
  2. Excludes cases which tested resistant in vitro
  3. a Includes both acute decompensated heart failure and NYHA IV heart failure
  4. b 5 patients had both non-urinary tract source and renal impairment (eGFR < 30 mL/min/1.73 m2) as contraindications
  5. c 1 patient had both cirrhosis and was dialysis dependent
  6. d 2 patients had both allergy and non-urinary tract source
  7. e Dialysis dependence for fosfomycin and eGFR < 30 mL/min/1.73 m2 for plazomicin